Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H1 2018

  • ID: 4473284
  • Report
  • 40 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Astellas Pharma Inc
  • Daiichi Sankyo Co Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • MORE
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H1 2018

Summary:

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Free Fatty Acid Receptor 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Free fatty acid receptor 1 (FFA1), also known as GPR40, is a class A G-protein coupled receptor that is encoded by the FFAR1 gene. It is strongly expressed in the pancreatic islet cells and to a lesser extent in the brain. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis.

The molecules developed by companies in Phase I and Preclinical stages are 1 and 9 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Type 2 Diabetes and Diabetes.

Furthermore, this report also reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
  • The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Astellas Pharma Inc
  • Daiichi Sankyo Co Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • MORE
Introduction

Report Coverage

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Overview

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development

Amgen Inc

Astellas Pharma Inc

Connexios Life Sciences Pvt Ltd

Daiichi Sankyo Co Ltd

Hyundai Pharmaceutical Co Ltd

Johnson & Johnson

Merck & Co Inc

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles

AM-1638 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-3189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-2575959 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNX-01167 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-1558 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HD-6277 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOB-047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-2305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize PPAR Gamma and GPR40 for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TUG-770 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Products

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Product Development Milestones

Featured News & Press Releases

Apr 10, 2012: Connexios in discussions to partner early-stage GPR40 diabetes drug, CRO will be chosen in US/EU -CEO

Jun 27, 2011: Connexios Life Science Presents Preclinical Data On CNX-011-67 At American Diabetes Association Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Amgen Inc, H1 2018

Pipeline by Astellas Pharma Inc, H1 2018

Pipeline by Connexios Life Sciences Pvt Ltd, H1 2018

Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2018

Pipeline by Johnson & Johnson, H1 2018

Pipeline by Merck & Co Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc
  • Astellas Pharma Inc
  • Connexios Life Sciences Pvt Ltd
  • Daiichi Sankyo Co Ltd
  • Hyundai Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Merck & Co Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll